Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 10/20 | 1.00 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5337617 | 0.85 | NQO2 (1.00) | NQO2MTNR1AMTNR1B | |
| SCHEMBL5342747 | 0.84 | NQO2 (1.00) | NQO2MTNR1AMTNR1B | |
| SCHEMBL5342615 | 0.83 | NQO2 (0.77) | NQO2MTNR1AMTNR1BLMNARECQL | |
| SCHEMBL5340374 | 0.82 | MTNR1A (1.00) | NQO2MTNR1AMTNR1B | |
| SCHEMBL5341459 | 0.82 | NQO2 (0.74) | NQO2MTNR1AMTNR1BLMNARECQL | |
| SCHEMBL5349376 | 0.81 | NQO2 (0.76) | NQO2MTNR1AMTNR1BLMNARECQL | |
| SCHEMBL7833216 | 0.80 | NQO2 (0.82) | NQO2MTNR1AMTNR1BLMNARECQL | |
| SCHEMBL5338767 | 0.79 | MTNR1A (1.00) | NQO2MTNR1AMTNR1B | |
| SCHEMBL5340850 | 0.79 | NQO2 (1.00) | NQO2MTNR1AMTNR1BLMNARECQL | |
| SCHEMBL6213554 | 0.78 | NQO2 (0.72) | NQO2MTNR1AMTNR1BMAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077928-B1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2005-12-07 | — | — | EP | claimed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | claimed |
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | NQO2 492/4885MTNR1A 388/4885MTNR1B 325/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | NQO2 450/4885MTNR1A 409/4885MTNR1B 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.